FIZE Medical, a leader in fluid management optimization, announced the closing of its $30 million Series A funding round, including a $14 million Series A-4 round led by Rapha Capital Management and its managed fund, Rapha Capital PE Life Sciences Fund VI. Joining this round is Valitas Venture Capital, known for its approach to go-to-market strategies in the healthcare sector. Also joining the round is eHealth Ventures, a strategic investor that provides access to global distribution channels, connections with key opinion leaders (KOLs), and a solid commercial network.
Valitas, co-founder and former Medtronic executive Tal Shnider, will join FIZE Medical’s board as an observer. And Yair Hadar, representing eHealth Ventures, will join FIZE Medical’s board as an observer.
FIZE Medical is a commercial-stage company, solidifying its position as a smart fluid management technology pioneer by expanding its geographical reach to the U.S., EU, and Asian markets. And the company is also advancing its technological development and is set to launch soon AI-based predictive capabilities that will serve as a Decision Support System (DSS) using advanced data analysis. The market for AI-based technologies in critical care is estimated at approximately $12 billion annually.
Managing the hemodynamic status of critically ill patients is a challenge for intensive care teams as inaccurate diagnosis leading to misguided treatment can lead to severe complications and is a leading cause of mortality in intensive care units. In the US alone, several million patients are hospitalized annually in intensive care units, with more than one-third experiencing circulatory shock, which carries a mortality rate of approximately 40%. Plus, around 50% of ICU patients develop AKI (Acute Kidney Injury) during hospitalization, resulting in mortality rates exceeding 20%. Early detection of AKI and Shock could significantly reduce morbidity and mortality rates.
The company’s technology meets the challenges with digital, continuous and real-time monitoring of kidney output. The data is streamed, minute by minute, in real-time, to a bedside device and the patient’s electronic medical record (EMR), providing proactive, never before available, accurate data of changes in kidney function to the medical team, alerting them to important events when they are determined by the FIZE kUO smart device. And by helping medical teams adjust therapies promptly, FIZE Medical’s innovation simplifies clinical decision-making, enables improved patient outcomes, aims to reduce mortality, and alleviates the workload on healthcare professionals.
The company also saw an impressive surge in demand in 2024, driving rapid development and operational growth. And over the next year, FIZE Medical plans to expand its platform to include advanced AI-driven patient condition predictions, intra-abdominal pressure measurement, and additional features to enhance patient care.
The Series A-4 funding was led by Rapha Capital Management, founded by its President, Kevin Slawin, M.D., a successful and experienced urologist, domain expert on the best practice for maintaining kidney health and Foley catheter management, oncologic and robotic surgeon, who is now focusing on advancing disruptive healthcare technologies.
KEY QUOTES:
“In response to the growing demand across both domestic and international markets, we have strategically expanded our production capabilities—strengthening internal operations while leveraging our partnership with Cicor facilities in Vietnam to ensure scalability and efficiency.”
– Sima Faifman Kuchersky, FIZE Medical’s Chief Commercial Officer
“We are thrilled to have Rapha Capital as the lead investor in this funding round, reaffirming their commitment to our mission. This funding, alongside support from Valitas Venture Capital, eHealth Ventures, and our existing investors, will enable us to accelerate our expansion into the U.S. and EU healthcare markets. With our innovative fluid management solutions, we look forward to positively impacting more hospitals and patients globally.”
– Dror Zerem, CEO of FIZE Medical
